Format

Send to

Choose Destination
Clin Lung Cancer. 2006 May;7(6):381-4.

Clinical development of SRC tyrosine kinase inhibitors in lung cancer.

Author information

1
CIG Media Group, LP, Dallas, TX, USA.

Abstract

Src tyrosine kinases regulate a large number of important mechanisms in normal and cancerous cells, are overexpressed in a broad range of tumors including lung cancer, and thus represent a potential target for cancer therapy. Preclinical experiments indicate that small-molecule inhibitors of Src block tumor growth, metastasis, and angiogenesis. Phase I data from healthy volunteers also suggest that inhibitors of Src prevent bone resorption. Several phase II trials with small-molecule inhibitors of Src are under way or have been initiated in lung cancer and in other malignancies, as discussed herein.

PMID:
16800962
DOI:
10.3816/clc.2006.n.020
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center